6-K
Alterity Therapeutics Ltd (ATHE)
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
FORM6-K
REPORTOF FOREIGN PRIVATE ISSUER
PURSUANTTO RULE 13a-16 OR 15d-163
UNDERTHE SECURITIES EXCHANGE ACT OF 1934
Forthe month of January 2025
AlterityTherapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street,Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicateby check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
ThisForm 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980and 333-228671) and ourRegistration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417and 333-250076)
ALTERITYTHERAPEUTICS LIMITED
(adevelopment stage enterprise)
The following exhibits are submitted:
| 99.1 | Trading Halt |
|---|
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | |
|---|---|
| By: | /s/ Geoffrey P. Kempler |
| Geoffrey P. Kempler | |
| Chairman |
Date: January 28, 2025
2
Exhibit 99.1
Market Announcement
28 January 2025
Alterity Therapeutics Limited (ASX: ATH) – Trading Halt
Description
The securities of Alterity Therapeutics Limited (‘ATH’) will be placed in trading halt at the request of ATH, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 30 January 2025 or when the announcement is released to the market.
Issued by
ASX Compliance
| 28 January 2025 | Market Announcement 1/1 | |
|---|---|---|
| ASX Limited | ASX Customer Service Centre 131 279 | asx.com.au |
28 January 2025
By email: melissa.kostopoulos@asx.com.au
Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne) ASX Limited
Dear Melissa
Request for a trading halt
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (the Company), requests that the Company’s securities be placed into a trading halt with immediate effect.
For the purposes of Listing Rule 17.1, the Company provides the following information:
| 1. | (a) the Company is seeking the trading halt pending an announcement<br>in relation to the results of its Phase II clinical trial; |
|---|---|
| 2. | (b) the Company requests that the trading halt continues<br>until the earlier of it making an announcement regarding the results of the Phase II clinical trial or until the commencement of trading<br>on Thursday 30 January 2025; and |
| --- | --- |
| 3. | (c) the Company is not aware of any reason why the trading<br>halt should not be granted or of any other information necessary to inform the market about the trading halt. |
| --- | --- |
Please contact us should you have any questions.
Yours sincerely
| /s/ Abby Macnish Niven |
|---|
Abby Macnish Niven
Company Secretary
For and on behalf of the Board of Alterity Therapeutics Limited
Alterity Therapeutics Limited
Level 3, 460 Bourke Street, Melbourne,VIC 3000 Australia
T: +61 (0)3 9349 4906 | WWW.alteritytherapeutics.com